CA2520708C - Antistatic medication delivery apparatus - Google Patents
Antistatic medication delivery apparatus Download PDFInfo
- Publication number
- CA2520708C CA2520708C CA2520708A CA2520708A CA2520708C CA 2520708 C CA2520708 C CA 2520708C CA 2520708 A CA2520708 A CA 2520708A CA 2520708 A CA2520708 A CA 2520708A CA 2520708 C CA2520708 C CA 2520708C
- Authority
- CA
- Canada
- Prior art keywords
- holding chamber
- antistatic
- backpiece
- ohm
- output end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 229940079593 drug Drugs 0.000 title claims abstract description 43
- 239000000463 material Substances 0.000 claims abstract description 48
- 229920003023 plastic Polymers 0.000 claims abstract description 16
- 239000004033 plastic Substances 0.000 claims abstract description 16
- 239000013536 elastomeric material Substances 0.000 claims abstract description 4
- -1 polypropylene Polymers 0.000 claims description 10
- 229920002725 thermoplastic elastomer Polymers 0.000 claims description 8
- 229920001971 elastomer Polymers 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 239000000806 elastomer Substances 0.000 claims description 5
- 229920001903 high density polyethylene Polymers 0.000 claims description 5
- 239000004700 high-density polyethylene Substances 0.000 claims description 5
- 229920000515 polycarbonate Polymers 0.000 claims description 5
- 239000004417 polycarbonate Substances 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 claims description 4
- 229940071648 metered dose inhaler Drugs 0.000 claims description 4
- 229920001707 polybutylene terephthalate Polymers 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 3
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 claims description 3
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 2
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920003225 polyurethane elastomer Polymers 0.000 claims description 2
- 229920006285 olefinic elastomer Polymers 0.000 claims 1
- 239000000443 aerosol Substances 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229940112141 dry powder inhaler Drugs 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000002216 antistatic agent Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920002943 EPDM rubber Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 2
- 229920002215 polytrimethylene terephthalate Polymers 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 229920006465 Styrenic thermoplastic elastomer Polymers 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920006236 copolyester elastomer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920002397 thermoplastic olefin Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0233—Conductive materials, e.g. antistatic coatings for spark prevention
Abstract
An aerosol medication delivery apparatus (50) include a holding chamber (4, 20) having an input end (6) and an output end (14) and defining an interior space (19). In one embodiment, the holding chamber is antistatic and is made of a plastic material having a surface resistivity of between about 10E 10 and about 10E 12 ohm/sq. In another embodiment, a component, such as a backpiece (22) or mouthpiece (102, 108, 110), separate from the holding chamber, is antistatic and is made of a material having a surface resistivity of between about 10E10 and about 10E12 ohm/sq. The component is connected to the holding chamber, which may or may not be antistatic. In one embodiment, the component is made of an elastomeric material. In one embodiment, at least a portion of the holding chamber and/or component is see~through. Various methods for introducing an aerosol into the holding chamber at the input end thereof and inhaling the aerosol through the output end are also provided.
Description
ANTISTATIC MEDICATION DELIVERY APPARATUS
BACKGROUND:
The present invention relates to a medication delivery apparatus, and in particular, to an antistatic medication delivery apparatus.
Medication delivery systems are used, in general, to administer medication to a user. For example, aerosol delivery systems are configured to deliver a medication in aerosol form to the lungs of the user. Other systems deliver the medication to the nasal passageways of the user. Some systems use a pressurized metered-dose inhaler (pMDI), which typically includes a container in which medication particles are stored under pressure, and an actuator used to dispense the medication from the container.
In other systems, a holding chamber or spacer is connected to one of the container or actuator, as shown for example in U.S. Patent No. 6,293,279, which may be referred to herein. The holding chamber reduces the need for the user to coordinate activation of the pMDI canister with inhalation, helps reduce the delivery of nonrespirable medication particles from the canister, and helps reduce the impaction of medication particles in the user's oropharnyx and upper airway. In some configurations, shown for example in the U.S. Patent No.
6,293,279 and U.S. Patent No. 5,881,718, the apparatus can be provided with one or both of an inhalation and exhalation valve(s) at an output end of the.
chamber.
The output end is typically configured with a mouthpiece, which is received in the mouth of the user, or with a mask, which is placed over the mouth and nose of the user.
Often, holding chamber devices are made of various plastics, such as polypropylene or polycarbonates. However, plastic materials typically have relative high surface resistivities, typically greater than 10E12 ohm/sq. As such, the interior of the chamber can become electrostatically charged, thereby causing some of the medication particles in the aerosol to deposit on the walls and/or other parts attached to or forming part of the holding chamber. As disclosed in U.S.
Patent No. 6,435,176, for example, one solution to this problem is to provide a spacer made of metal or other materials having resistivities below 10E9 ohm.
However, metal spacers or holding chambers, made for example of stainless steel or aluminum, are relatively expensive to manufacture and are heavy and more difficult to handle. In addition, metal spacers or holding chambers do not allow the user or caregiver to visualize the delivery of medication from the chamber.
Likewise, many plastics, if formed with antistatic additives, such as metal fibers, are not see-through and can obstruct a view of the interior of the chamber. In addition, plastic components having an antistatic surface coating can tend to degrade and lose their antistatic properties over time, e.g., within about a year.
Another solution is to periodically wash a plastic holding chamber with a detergent. However, such a solution can be cumbersome. Accordingly, the need remains for an improved holding chamber made of plastic, preferably clear, having inherent substantially permanent antistatic properties.
SUMMARY
By way of introduction, various preferred embodiments of an aerosol medication delivery apparatus include a holding chamber having an input end and an output end and defining an interior space. In one embodiment, the holding chamber is antistatic and is made of a plastic material having a surface resistivity of less than about IOE12ohm/sq, and preferably between about 10E10 and about 10E12 ohm/sq. In one preferred embodiment, at least a portion of the holding chamber is see-through. In addition, the antistatic properties are substantially permanent.
In another embodiment, a component, separate from the holding chamber, is antistatic and is made of a material having a surface resistivity of between about 10E10 and about 1OE12 ohm/sq. The component is connected, directly or indirectly, to the holding chamber, which may or may not be antistatic. In one preferred embodiment, the component is a backpiece connected to an input end of the holding chamber. In one embodiment, the backpiece is made of an elastomeric material. In another embodiment, the component includes a mouthpiece connected to the output end of the holding chamber.
In other aspects, various methods are provided that include introducing an aerosol into the holding chamber at the input end thereof and inhaling the aerosol through the output end.
The various embodiments provide significant advantages over other holding chamber devices. For example, both the holding chamber and component, such as the backpiece, can be made of various plastic and/or elastomeric materials, which are relatively light weight and inexpensive to manufacture. At the same time, one or more of the holding chamber and components can be made antistatic, such that the medication particles in the aerosol are less likely to be attracted to the interior surface of the holding chamber or components, thereby providing improved consistency in the amount of medication delivered to the patient without pretreating the delivery apparatus. In addition, the plastic material can be made see-through, such that the user or caretaker can monitor and visualize the interior of the holding chamber and/or component. Moreover, the antistatic properties are substantially permanent, such that they do not degrade over time.
The foregoing paragraphs have been provided by way of general introduction, and are not intended to limit the scope of the following claims.
The presently preferred embodiments, together with further advantages, will be best understood by reference to the following detailed description taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 is a perspective view of a first embodiment of an aerosol medication delivery system.
FIGURE 2 is an exploded perspective view of the aerosol medication delivery system shown in FIG. 1.
FIGURE 3 is a side cross-sectional view of an alternative embodiment of a holding chamber.
BACKGROUND:
The present invention relates to a medication delivery apparatus, and in particular, to an antistatic medication delivery apparatus.
Medication delivery systems are used, in general, to administer medication to a user. For example, aerosol delivery systems are configured to deliver a medication in aerosol form to the lungs of the user. Other systems deliver the medication to the nasal passageways of the user. Some systems use a pressurized metered-dose inhaler (pMDI), which typically includes a container in which medication particles are stored under pressure, and an actuator used to dispense the medication from the container.
In other systems, a holding chamber or spacer is connected to one of the container or actuator, as shown for example in U.S. Patent No. 6,293,279, which may be referred to herein. The holding chamber reduces the need for the user to coordinate activation of the pMDI canister with inhalation, helps reduce the delivery of nonrespirable medication particles from the canister, and helps reduce the impaction of medication particles in the user's oropharnyx and upper airway. In some configurations, shown for example in the U.S. Patent No.
6,293,279 and U.S. Patent No. 5,881,718, the apparatus can be provided with one or both of an inhalation and exhalation valve(s) at an output end of the.
chamber.
The output end is typically configured with a mouthpiece, which is received in the mouth of the user, or with a mask, which is placed over the mouth and nose of the user.
Often, holding chamber devices are made of various plastics, such as polypropylene or polycarbonates. However, plastic materials typically have relative high surface resistivities, typically greater than 10E12 ohm/sq. As such, the interior of the chamber can become electrostatically charged, thereby causing some of the medication particles in the aerosol to deposit on the walls and/or other parts attached to or forming part of the holding chamber. As disclosed in U.S.
Patent No. 6,435,176, for example, one solution to this problem is to provide a spacer made of metal or other materials having resistivities below 10E9 ohm.
However, metal spacers or holding chambers, made for example of stainless steel or aluminum, are relatively expensive to manufacture and are heavy and more difficult to handle. In addition, metal spacers or holding chambers do not allow the user or caregiver to visualize the delivery of medication from the chamber.
Likewise, many plastics, if formed with antistatic additives, such as metal fibers, are not see-through and can obstruct a view of the interior of the chamber. In addition, plastic components having an antistatic surface coating can tend to degrade and lose their antistatic properties over time, e.g., within about a year.
Another solution is to periodically wash a plastic holding chamber with a detergent. However, such a solution can be cumbersome. Accordingly, the need remains for an improved holding chamber made of plastic, preferably clear, having inherent substantially permanent antistatic properties.
SUMMARY
By way of introduction, various preferred embodiments of an aerosol medication delivery apparatus include a holding chamber having an input end and an output end and defining an interior space. In one embodiment, the holding chamber is antistatic and is made of a plastic material having a surface resistivity of less than about IOE12ohm/sq, and preferably between about 10E10 and about 10E12 ohm/sq. In one preferred embodiment, at least a portion of the holding chamber is see-through. In addition, the antistatic properties are substantially permanent.
In another embodiment, a component, separate from the holding chamber, is antistatic and is made of a material having a surface resistivity of between about 10E10 and about 1OE12 ohm/sq. The component is connected, directly or indirectly, to the holding chamber, which may or may not be antistatic. In one preferred embodiment, the component is a backpiece connected to an input end of the holding chamber. In one embodiment, the backpiece is made of an elastomeric material. In another embodiment, the component includes a mouthpiece connected to the output end of the holding chamber.
In other aspects, various methods are provided that include introducing an aerosol into the holding chamber at the input end thereof and inhaling the aerosol through the output end.
The various embodiments provide significant advantages over other holding chamber devices. For example, both the holding chamber and component, such as the backpiece, can be made of various plastic and/or elastomeric materials, which are relatively light weight and inexpensive to manufacture. At the same time, one or more of the holding chamber and components can be made antistatic, such that the medication particles in the aerosol are less likely to be attracted to the interior surface of the holding chamber or components, thereby providing improved consistency in the amount of medication delivered to the patient without pretreating the delivery apparatus. In addition, the plastic material can be made see-through, such that the user or caretaker can monitor and visualize the interior of the holding chamber and/or component. Moreover, the antistatic properties are substantially permanent, such that they do not degrade over time.
The foregoing paragraphs have been provided by way of general introduction, and are not intended to limit the scope of the following claims.
The presently preferred embodiments, together with further advantages, will be best understood by reference to the following detailed description taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 is a perspective view of a first embodiment of an aerosol medication delivery system.
FIGURE 2 is an exploded perspective view of the aerosol medication delivery system shown in FIG. 1.
FIGURE 3 is a side cross-sectional view of an alternative embodiment of a holding chamber.
FIGURE 4 is a side cross-sectional view of an alternative embodiment of a medication delivery system.
FIGURE 5 is a side cross-sectional view of an alternative embodiment of a medication delivery system.
FIGURE 6 is an exploded perspective view of an alternative embodiment of a medication delivery system.
FIGURE 7 is an exploded perspective view of an alternative embodiment of a medication delivery system.
FIGURE 8 is an exploded perspective view of an alternative embodiment of a medication delivery system.
FIGURE 9 is an exploded perspective view of an alternative embodiment of a medication delivery system.
FIGURE 10 is a partial side view of an output end of an alternative embodiment of a holding chamber.
FIGURE 11 is a perspective view of one embodiment of a dry powder inhaler.
FIGURE 12 is a top view of an alternative embodiment of a dry powder inhaler.
FIGURE 13 is an end view of the dry powder inhaler shown in Fig. 12.
FIGURE 14 is an exploded perspective view of an alternative embodiment of a dry powder inhaler.
FIGURE 15 is a perspective view of the dry powder inhaler shown in Fig.
14.
FIGURE 16 is a side view of a nasal inhaler.
DETAILED DESCRIPTION OF THE
PRESENTLY PREFERRED EMBODIMENTS
Referring to FIGS. 1, 2 and 6, one preferred embodiment of an aerosol medication delivery system 50 includes a pressurized metered dose inhaler (pMDI) holding portion 2, or dispenser (sometimes referred to as an actuator boot), coupled to a chamber housing 4, otherwise referred to as a holding chamber, at an input end 6 thereof. A medication container 8, for example a pMDI
canister, is disposed in a cavity 12 formed in the dispenser, with a stem of the canister being inserted into a well 10 formed in the bottom of the dispenser.
Preferably, the dispenser 2 is pivotally connected to the chamber housing 4 so that the dispenser 2 can be pivoted and translated for storage inside the chamber housing 5 when the device is not in use. The term "medication" or "medicament" and variations thereof as used herein means any substance used in therapy, for example in the treatment of asthma.
In various alternative embodiments shown in FIGS. 3, 4 and 7-9, the apparatus includes a backpiece 22 secured to a holding chamber 20, 90 at an input end 52, 94 thereof. The backpiece 22, which is preferably formed as a separate component from the holding chamber, includes an opening 24 shaped to receive a mouthpiece portion 54 of a separate pMDI dispenser 156, which holds the container 8. Various configurations of chamber housings and dispensers are shown in U.S. Patent Nos. 6,293,279, 5,012,803 and 5,012,804, the entire disclosures of which may be referred to herein. It should be understood that a holding chamber can also be used in conjunction with medication delivery containers other than a pMDI container, including for example and without limitation nasal sprayers, dry powder inhalers and nebulizer systems.
In yet another embodiment, shown in FIG. 5, the apparatus. includes a holding chamber 70 that can be introduced into the inspiratory flow path of a ventilator circuit 302. The apparatus includes a backpiece member 72, configured with a pMDI receptacle 76, which is connected to the input end 79 of the holding chamber. The receptacle 76 is configured as a cylindrical housing shaped to receive the pMDI container and includes a well 10 formed at the bottom of the receptacle shaped to receive a pMDI valve stem 78. A discharge opening 80 is formed in the receptacle and communicates with the well 10, thereby allowing the aerosol, and medication, to be introduced into an interior 32 of the holding chamber through the backpiece 72 and input end 74 of the holding chamber.
In all of the embodiments, the chamber housing 4, 20, 70 defines an interior space 19, 56, 82 and further includes an output end 14, 58, 84, 94, through which the medication is dispensed to the user. The holding chamber 20 can have a substantially circular cross section as shown for example in FIG. 7, or the holding chamber 4 can have other shapes, for example a substantially oval cross-section as shown in FIG. I or an elliptical or rectangular cross-section (not shown). In addition, the holding chamber 20 can have a substantially constant cross-section, for example forming a cylinder as shown in FIG. 7, or the holding chamber 20 can be tapered, such that the cross-sectional area gradually increases from the input end 92 to the output end 94 as shown in FIGS. 8 and 9, or decreases along the same path (not shown).
As shown in the embodiments of FIGS. 1-3 and 6-8, the output end 14, 58, 84, 94 includes a downstream portion 23 that is configured with a mouthpiece 102, 104, 106, 108, 110. The mouthpiece 102, 106, 108, 110 can be formed as a separate component that is releasably secured to a main housing 21 with one or more fastening elements 25, 27, as shown for example in FIGS. 1, 2, and 4-8.
For example, the fastening elements can be configured as tabs 25 and recesses 24 in one preferred embodiment, which provides a snap-fit between the main housing and the downstream portion 23. As shown in FIG. 3, the mouthpiece 104 can alternatively be formed integrally with the housing.
The term "component" as used herein means any part, member, device, or feature that forms part of the medication delivery apparatus, and includes without limitation, the chamber housing, the backpiece, the mouthpiece, the output end, various adapters, baffle members, actuators, valve assemblies, tubes or conduits, masks, and the like, and portions thereof, which are incorporated into the system.
The terms "connected" and "secured," and variations thereof, us used herein, means that one or more members are associated or coupled to each other, either directly or indirectly (for example with intervening members).
In one alternative embodiment, shown in FIG. 10, an adapter 30 includes an input end 32 configured as an insert portion that is fitted in an opening formed in an output end 64 of a chamber housing 66. Conversely, the input end 32 can be fitted over or around an end portion of the chamber housing. In one embodiment, the adapter includes a narrow orifice, as disclosed for example in U.S.
FIGURE 5 is a side cross-sectional view of an alternative embodiment of a medication delivery system.
FIGURE 6 is an exploded perspective view of an alternative embodiment of a medication delivery system.
FIGURE 7 is an exploded perspective view of an alternative embodiment of a medication delivery system.
FIGURE 8 is an exploded perspective view of an alternative embodiment of a medication delivery system.
FIGURE 9 is an exploded perspective view of an alternative embodiment of a medication delivery system.
FIGURE 10 is a partial side view of an output end of an alternative embodiment of a holding chamber.
FIGURE 11 is a perspective view of one embodiment of a dry powder inhaler.
FIGURE 12 is a top view of an alternative embodiment of a dry powder inhaler.
FIGURE 13 is an end view of the dry powder inhaler shown in Fig. 12.
FIGURE 14 is an exploded perspective view of an alternative embodiment of a dry powder inhaler.
FIGURE 15 is a perspective view of the dry powder inhaler shown in Fig.
14.
FIGURE 16 is a side view of a nasal inhaler.
DETAILED DESCRIPTION OF THE
PRESENTLY PREFERRED EMBODIMENTS
Referring to FIGS. 1, 2 and 6, one preferred embodiment of an aerosol medication delivery system 50 includes a pressurized metered dose inhaler (pMDI) holding portion 2, or dispenser (sometimes referred to as an actuator boot), coupled to a chamber housing 4, otherwise referred to as a holding chamber, at an input end 6 thereof. A medication container 8, for example a pMDI
canister, is disposed in a cavity 12 formed in the dispenser, with a stem of the canister being inserted into a well 10 formed in the bottom of the dispenser.
Preferably, the dispenser 2 is pivotally connected to the chamber housing 4 so that the dispenser 2 can be pivoted and translated for storage inside the chamber housing 5 when the device is not in use. The term "medication" or "medicament" and variations thereof as used herein means any substance used in therapy, for example in the treatment of asthma.
In various alternative embodiments shown in FIGS. 3, 4 and 7-9, the apparatus includes a backpiece 22 secured to a holding chamber 20, 90 at an input end 52, 94 thereof. The backpiece 22, which is preferably formed as a separate component from the holding chamber, includes an opening 24 shaped to receive a mouthpiece portion 54 of a separate pMDI dispenser 156, which holds the container 8. Various configurations of chamber housings and dispensers are shown in U.S. Patent Nos. 6,293,279, 5,012,803 and 5,012,804, the entire disclosures of which may be referred to herein. It should be understood that a holding chamber can also be used in conjunction with medication delivery containers other than a pMDI container, including for example and without limitation nasal sprayers, dry powder inhalers and nebulizer systems.
In yet another embodiment, shown in FIG. 5, the apparatus. includes a holding chamber 70 that can be introduced into the inspiratory flow path of a ventilator circuit 302. The apparatus includes a backpiece member 72, configured with a pMDI receptacle 76, which is connected to the input end 79 of the holding chamber. The receptacle 76 is configured as a cylindrical housing shaped to receive the pMDI container and includes a well 10 formed at the bottom of the receptacle shaped to receive a pMDI valve stem 78. A discharge opening 80 is formed in the receptacle and communicates with the well 10, thereby allowing the aerosol, and medication, to be introduced into an interior 32 of the holding chamber through the backpiece 72 and input end 74 of the holding chamber.
In all of the embodiments, the chamber housing 4, 20, 70 defines an interior space 19, 56, 82 and further includes an output end 14, 58, 84, 94, through which the medication is dispensed to the user. The holding chamber 20 can have a substantially circular cross section as shown for example in FIG. 7, or the holding chamber 4 can have other shapes, for example a substantially oval cross-section as shown in FIG. I or an elliptical or rectangular cross-section (not shown). In addition, the holding chamber 20 can have a substantially constant cross-section, for example forming a cylinder as shown in FIG. 7, or the holding chamber 20 can be tapered, such that the cross-sectional area gradually increases from the input end 92 to the output end 94 as shown in FIGS. 8 and 9, or decreases along the same path (not shown).
As shown in the embodiments of FIGS. 1-3 and 6-8, the output end 14, 58, 84, 94 includes a downstream portion 23 that is configured with a mouthpiece 102, 104, 106, 108, 110. The mouthpiece 102, 106, 108, 110 can be formed as a separate component that is releasably secured to a main housing 21 with one or more fastening elements 25, 27, as shown for example in FIGS. 1, 2, and 4-8.
For example, the fastening elements can be configured as tabs 25 and recesses 24 in one preferred embodiment, which provides a snap-fit between the main housing and the downstream portion 23. As shown in FIG. 3, the mouthpiece 104 can alternatively be formed integrally with the housing.
The term "component" as used herein means any part, member, device, or feature that forms part of the medication delivery apparatus, and includes without limitation, the chamber housing, the backpiece, the mouthpiece, the output end, various adapters, baffle members, actuators, valve assemblies, tubes or conduits, masks, and the like, and portions thereof, which are incorporated into the system.
The terms "connected" and "secured," and variations thereof, us used herein, means that one or more members are associated or coupled to each other, either directly or indirectly (for example with intervening members).
In one alternative embodiment, shown in FIG. 10, an adapter 30 includes an input end 32 configured as an insert portion that is fitted in an opening formed in an output end 64 of a chamber housing 66. Conversely, the input end 32 can be fitted over or around an end portion of the chamber housing. In one embodiment, the adapter includes a narrow orifice, as disclosed for example in U.S.
Patent No. 7,201,164 dated April 10, 2007 and entitled "Aerosol Medication Delivery Apparatus With Narrow Orifice," the entire disclosure of which may be referred to herein. The adapter further includes an output end 34 that, in one preferred embodiment, is shaped to be received in the mouth of the user. For example, the output end 34 can have an outer circular cross-section, or it can be elliptical, oval, obround or any other shaped suitable for insertion into the mouth of the user. Alternatively, an additional mouthpiece (not shown) can be fitted in or around the output end.
In yet another alternative embodiment, shown in FIG. 9, a mask 160 is fitted in or around, i.e. a connector member 300, secured to the output end of the holding chamber. The mask 160 is shaped to be disposed over the face, preferably including the mouth and nose, of the user. In yet another alternative embodiment, a nasal applicator (not shown), provided for example with prongs, can be fitted into or around the output and. In yet another embodiment, a patient interface element, such as an endotracheal tube, can be fitted to one or more of the output end of the holding chamber or adapter.
In all of the embodiments, shown for example in FIGS. 1-9, the output and 14, 58, 84, 94 of the holding chamber 4, 20, 70, 90 can be configured with a baffle member 200. The baffle member 200 is preferably curved, and can have one or more concave or convex surfaces facing toward and away from the input and of the holding chamber. Of course, it should be understood that the baffle member 200 can be flat,. or have other non-curved shapes. In addition, it should be understood that the apparatus can be configured without a baffle formed at the output end of the holding chamber.
As shown in FIGS. 6-9, the output end of the holding chamber can be configured with one or both of an inhalation and exhalation valve 220. In one embodiment, shown in FIG. 7, the valve 220 includes a central open area 224 having a peripheral edge portion 226 that seats on a valve seat formed on a center baffle portion 228 of the baffle member 200. The valve is displaced from the seat during inhalation. An outer peripheral portion 230 of the valve is seated on a second valve seat and is displaced therefrom during exhalation. Of course, it should be understood that other valve configurations, such as a duckbill valve, can also be used.
The valve member 220 is preferably made of a flexible material, including for example and without limitation a silicone, a thermoplastic elastomer, rubber, Ethylene-Propylene-Diene-Monomer (EPDM) or Berfluodelaastomers (FFKN).
Preferably, the adapter 30 and the chamber housing 4, 20, 70, 90 are made of a hard antistatic plastic, for example by injection molding. Typically, plastics have a surface resistivity of greater than 10E12 ohm/sq. Antistatic materials have a surface resistivity of between about 1 OE 10 ohm/sq and about 1 OE 12 ohm/sq.
Static dissipative materials have a surface resistivity of between about 10E6 ohm/sq. and about 1 OE 12 ohm/sq. Conductive materials have a surface resistivity of between about 1 OE1 ohm/sq and about 10E6 ohm/sq. Metals typically have a surface resistivity of between about 1OE-1 to about 1OE-5 ohm/sq. Surface resistivity as set forth herein is measured pursuant to ASTM test D257.
In various embodiments, the chamber housing 4, 20, 70, 90, adapter 30, mouthpiece 102, 106, 108, 110, and/or backpiece 22, 72 are made of one or more of a polypropylene, polycarbonate, polystyrene, nylon, ABS, high density polyethylene (HDPE), acetal, PBT, PETG, various thermoplastic elastomers, and/or combinations thereof. For example, the components can be made of various PermaStat compounds available from the RTP Company, having a place of business at 580 East Front Street, Winona, Minnesota, 55987. Of course, it should be understood that materials other than PermaStat compounds are suitable. In any event, the materials preferably have a surface resistivity of less than about 1 OE 12 ohm/sq, more preferably between about 1OE1 and about 1 OE
ohm/sq, more preferably between about 10E6 and about 10E 12 ohm/sq, more preferably between about 1OE10 and about 10E12 ohm/sq, and most preferably between about 1OE10 and about 1OE11 ohm/sq.
In various exemplary embodiments, and without limitation, the chamber housing 4, 20, 70, 90, adapter 30, mouthpiece 102, 106, 108, 110, and backpiece 22, 72 can be made from one or more of a PermaStat 100 series polypropylene material, a PermaStat 200 series Nylon (PA6, PA6/6 or P12) material, a PermaStat 300 series polycarbonate material, a PermaStat 400 series polystyrene (PS) material, a PermaStat 600 series Acrylonitrile Butadiene Styrene (ABS) material, a PermaStat 700 series high density polyethylene (HDPE) material, a PermaStat 800 series Acetal (POM) material, a PermaStat 1000 series polybutylene Terephthalate (PBT) material, a PermaStat 1100 series polyethylene Terephthalate Glycol modified (PETG) material, a PermaStat 1200 series polyurethane thermoplastic elastomer material, a PermaStat 1500 series polyester thermoplastic elastomer, a PermaStat 1800 series acrylic (PMMA) material, a PermaStat 2500 series polycarbonate/ABS alloy material, a PermaStat 2700 series Styrenic thermoplastic elastomer (TES) material, a PermaStat 2800 series Olefinic thermoplastic elastomer (TEO) materials, or a PermaStat 4700 series polytrimethylene Terephthalate (PTT) material, all being permanently anti-static and having a surface resistivity between about 1 OE 10 and about 1OE11 ohms/sq with electrical shock discharge (ESD) protection.
PermaStat compounds are colorable and retain the transparency of the host resin.
Such compounds are further free of carbon black, and are non-sloughing, meaning they do not release conductive contaminants. The compounds are further formulated to meet MIL-PRF-81705D static decay requirements. Since the compound is compounded into the molded material, the component is more robust and can function in all humidity levels. The term "plastic" as used herein includes thermoplastic elastomer materials.
Preferably, the chamber housing 4, 20, 70, mouthpiece 102, 106, 108, 110and adapter 30 are made of an RTP 199 X 95281 S Nat/Clear, available from the RTP Company. Another suitable material is the RTP 199 X 95281 U
Nat/Clear material, which is a high temperature material, also available from RTP
Company.
Preferably, the backpiece 22, 72 is made of one or more of the elastomeric materials, or other elastomers available from RTP, including for example the RTP
1200 series Polyurethane elastomers, the 1500 series copolyester elastomers, the 2700 series styrenic elastomers and/or the 2800 series olefmic elastomers. It should be understood that the backpiece 22, 72 also can be made of non-elastomeric materials. In addition, it should be understood that the holding chamber 4, 20, 70, 90, and various components, including without limitation, the adapter, mouthpiece and backpiece can be made of materials that are not antistatic, having for example surface resitivities of greater than 10E12 ohm/sq.
Therefore, 5 for example, the delivery apparatus may be configured with only the holding chamber 4, 20, 70, 90 being antistatic, only one or more of the various components being antistatic, such as the backpiece, mouthpiece and/or adapter but not the holding chamber, or all of the components including the holding chamber being antistatic.
In yet another alternative embodiment, shown in FIG. 9, a mask 160 is fitted in or around, i.e. a connector member 300, secured to the output end of the holding chamber. The mask 160 is shaped to be disposed over the face, preferably including the mouth and nose, of the user. In yet another alternative embodiment, a nasal applicator (not shown), provided for example with prongs, can be fitted into or around the output and. In yet another embodiment, a patient interface element, such as an endotracheal tube, can be fitted to one or more of the output end of the holding chamber or adapter.
In all of the embodiments, shown for example in FIGS. 1-9, the output and 14, 58, 84, 94 of the holding chamber 4, 20, 70, 90 can be configured with a baffle member 200. The baffle member 200 is preferably curved, and can have one or more concave or convex surfaces facing toward and away from the input and of the holding chamber. Of course, it should be understood that the baffle member 200 can be flat,. or have other non-curved shapes. In addition, it should be understood that the apparatus can be configured without a baffle formed at the output end of the holding chamber.
As shown in FIGS. 6-9, the output end of the holding chamber can be configured with one or both of an inhalation and exhalation valve 220. In one embodiment, shown in FIG. 7, the valve 220 includes a central open area 224 having a peripheral edge portion 226 that seats on a valve seat formed on a center baffle portion 228 of the baffle member 200. The valve is displaced from the seat during inhalation. An outer peripheral portion 230 of the valve is seated on a second valve seat and is displaced therefrom during exhalation. Of course, it should be understood that other valve configurations, such as a duckbill valve, can also be used.
The valve member 220 is preferably made of a flexible material, including for example and without limitation a silicone, a thermoplastic elastomer, rubber, Ethylene-Propylene-Diene-Monomer (EPDM) or Berfluodelaastomers (FFKN).
Preferably, the adapter 30 and the chamber housing 4, 20, 70, 90 are made of a hard antistatic plastic, for example by injection molding. Typically, plastics have a surface resistivity of greater than 10E12 ohm/sq. Antistatic materials have a surface resistivity of between about 1 OE 10 ohm/sq and about 1 OE 12 ohm/sq.
Static dissipative materials have a surface resistivity of between about 10E6 ohm/sq. and about 1 OE 12 ohm/sq. Conductive materials have a surface resistivity of between about 1 OE1 ohm/sq and about 10E6 ohm/sq. Metals typically have a surface resistivity of between about 1OE-1 to about 1OE-5 ohm/sq. Surface resistivity as set forth herein is measured pursuant to ASTM test D257.
In various embodiments, the chamber housing 4, 20, 70, 90, adapter 30, mouthpiece 102, 106, 108, 110, and/or backpiece 22, 72 are made of one or more of a polypropylene, polycarbonate, polystyrene, nylon, ABS, high density polyethylene (HDPE), acetal, PBT, PETG, various thermoplastic elastomers, and/or combinations thereof. For example, the components can be made of various PermaStat compounds available from the RTP Company, having a place of business at 580 East Front Street, Winona, Minnesota, 55987. Of course, it should be understood that materials other than PermaStat compounds are suitable. In any event, the materials preferably have a surface resistivity of less than about 1 OE 12 ohm/sq, more preferably between about 1OE1 and about 1 OE
ohm/sq, more preferably between about 10E6 and about 10E 12 ohm/sq, more preferably between about 1OE10 and about 10E12 ohm/sq, and most preferably between about 1OE10 and about 1OE11 ohm/sq.
In various exemplary embodiments, and without limitation, the chamber housing 4, 20, 70, 90, adapter 30, mouthpiece 102, 106, 108, 110, and backpiece 22, 72 can be made from one or more of a PermaStat 100 series polypropylene material, a PermaStat 200 series Nylon (PA6, PA6/6 or P12) material, a PermaStat 300 series polycarbonate material, a PermaStat 400 series polystyrene (PS) material, a PermaStat 600 series Acrylonitrile Butadiene Styrene (ABS) material, a PermaStat 700 series high density polyethylene (HDPE) material, a PermaStat 800 series Acetal (POM) material, a PermaStat 1000 series polybutylene Terephthalate (PBT) material, a PermaStat 1100 series polyethylene Terephthalate Glycol modified (PETG) material, a PermaStat 1200 series polyurethane thermoplastic elastomer material, a PermaStat 1500 series polyester thermoplastic elastomer, a PermaStat 1800 series acrylic (PMMA) material, a PermaStat 2500 series polycarbonate/ABS alloy material, a PermaStat 2700 series Styrenic thermoplastic elastomer (TES) material, a PermaStat 2800 series Olefinic thermoplastic elastomer (TEO) materials, or a PermaStat 4700 series polytrimethylene Terephthalate (PTT) material, all being permanently anti-static and having a surface resistivity between about 1 OE 10 and about 1OE11 ohms/sq with electrical shock discharge (ESD) protection.
PermaStat compounds are colorable and retain the transparency of the host resin.
Such compounds are further free of carbon black, and are non-sloughing, meaning they do not release conductive contaminants. The compounds are further formulated to meet MIL-PRF-81705D static decay requirements. Since the compound is compounded into the molded material, the component is more robust and can function in all humidity levels. The term "plastic" as used herein includes thermoplastic elastomer materials.
Preferably, the chamber housing 4, 20, 70, mouthpiece 102, 106, 108, 110and adapter 30 are made of an RTP 199 X 95281 S Nat/Clear, available from the RTP Company. Another suitable material is the RTP 199 X 95281 U
Nat/Clear material, which is a high temperature material, also available from RTP
Company.
Preferably, the backpiece 22, 72 is made of one or more of the elastomeric materials, or other elastomers available from RTP, including for example the RTP
1200 series Polyurethane elastomers, the 1500 series copolyester elastomers, the 2700 series styrenic elastomers and/or the 2800 series olefmic elastomers. It should be understood that the backpiece 22, 72 also can be made of non-elastomeric materials. In addition, it should be understood that the holding chamber 4, 20, 70, 90, and various components, including without limitation, the adapter, mouthpiece and backpiece can be made of materials that are not antistatic, having for example surface resitivities of greater than 10E12 ohm/sq.
Therefore, 5 for example, the delivery apparatus may be configured with only the holding chamber 4, 20, 70, 90 being antistatic, only one or more of the various components being antistatic, such as the backpiece, mouthpiece and/or adapter but not the holding chamber, or all of the components including the holding chamber being antistatic.
10 Preferably, the antistatic material is substantially clear, such that at least a portion of the various components, including without limitation the holding chamber, backpiece, mouthpiece and adapters, are see-through such that the user can monitor the interior of the delivery apparatus. In this way, the term "clear"
simply means see-through, and includes materials that are completely transparent, as well as materials that are opaque or shaded, so long as an object is visible on the other side of the material. For example, by providing one or more see-through components, various visual flow indicators can be seen. Such visual indicators are shown for example in U.S. Patent No. 6,904,908 dated June 14, 2005, the entire disclosure of which may be referred to herein. In addition, the antistatic properties associated with various afore-described materials are substantially permanent, and will not dissipate over time.
in other embodiments, the holding chamber 4, 20, 70, 90, and other components, including for example and without limitation the adapter 30, mouthpiece 102, 106, 108, 110 and backpiece 22, 72, are made of various thermoplastics using various levels of additives, including without limitation, stainless steel fibers, carbon fibers and carbon powder. It should be understood that an antistatic coating also can be applied to the chamber housing and components, such as the adapter, mouthpiece and backpiece to achieve the desired resistivities.
In operation, the user actuates the dispenser 2, 156 or other device, so as to discharge a medication, preferably in aerosol form, through the input end 6, 52, 74 and introduce the medication into the interior space 19, 56, 82 of the holding chamber 4, 20, 70, 90, or chamber housing. The medication is thereafter delivered to the user, for example by inhalation through the output end 14, 58, 84 of the holding chamber, by way of one or more of a mouthpiece, mask or endotracheal tube. The antistatic properties of the holding chamber and back-piece reduce the likelihood that the medication particles will be attracted thereto.
Referring to FIGS. 10-15, exemplary powder medication delivery systems, or dry powder inhalers 400 are shown. Each inhaler 400 includes a holding chamber 402 and a mouthpiece 408. The inhaler shown in FIGS. 14 and 15, further includes a visual flow indicator 412 mounted within a viewing port area 410. The flow indicator moves within the port area to provide a visual cue to the patient or caretaker that the inhalation flow is adequate to properly administer the medication to the patient. Various aspects of the inhaler are further disclosed and shown in U.S. Patent No. 6,904,908 dated June 14, 2005, the entire disclosure of which may be referred to herein.
Referring to the inhaler in FIGS. 11-13, the inhaler 400 includes a holding chamber 402 and a mouthpiece 408, which can be separate from (FIG. 11) or integral with (FIGS. 12-13) the holding chamber. The inhaler further includes a medicament holding cassette 414, which has a plurality of holding portions 416 that hold a plurality of dose of medication, each of which can be subsequently exposed to the interior of the holding chamber. One or more air entry passageways 418 are directed at the holding' portions 416 and fluidize the medication within the holding chamber, wherein it can be subsequently inhaled through the mouthpiece. Various aspects of the inhaler are further disclosed and shown in U.S. Patent No. 6,116,239, the entire disclosure of which may be referred to herein.
It should be understood that any or all of the various components of the inhalers 400, including the holding chambers 402, mouthpieces 408, air intake passageways 418, cassettes 414, and/or holding portions 416, can be made of one or more of the various antistatic materials described herein.
simply means see-through, and includes materials that are completely transparent, as well as materials that are opaque or shaded, so long as an object is visible on the other side of the material. For example, by providing one or more see-through components, various visual flow indicators can be seen. Such visual indicators are shown for example in U.S. Patent No. 6,904,908 dated June 14, 2005, the entire disclosure of which may be referred to herein. In addition, the antistatic properties associated with various afore-described materials are substantially permanent, and will not dissipate over time.
in other embodiments, the holding chamber 4, 20, 70, 90, and other components, including for example and without limitation the adapter 30, mouthpiece 102, 106, 108, 110 and backpiece 22, 72, are made of various thermoplastics using various levels of additives, including without limitation, stainless steel fibers, carbon fibers and carbon powder. It should be understood that an antistatic coating also can be applied to the chamber housing and components, such as the adapter, mouthpiece and backpiece to achieve the desired resistivities.
In operation, the user actuates the dispenser 2, 156 or other device, so as to discharge a medication, preferably in aerosol form, through the input end 6, 52, 74 and introduce the medication into the interior space 19, 56, 82 of the holding chamber 4, 20, 70, 90, or chamber housing. The medication is thereafter delivered to the user, for example by inhalation through the output end 14, 58, 84 of the holding chamber, by way of one or more of a mouthpiece, mask or endotracheal tube. The antistatic properties of the holding chamber and back-piece reduce the likelihood that the medication particles will be attracted thereto.
Referring to FIGS. 10-15, exemplary powder medication delivery systems, or dry powder inhalers 400 are shown. Each inhaler 400 includes a holding chamber 402 and a mouthpiece 408. The inhaler shown in FIGS. 14 and 15, further includes a visual flow indicator 412 mounted within a viewing port area 410. The flow indicator moves within the port area to provide a visual cue to the patient or caretaker that the inhalation flow is adequate to properly administer the medication to the patient. Various aspects of the inhaler are further disclosed and shown in U.S. Patent No. 6,904,908 dated June 14, 2005, the entire disclosure of which may be referred to herein.
Referring to the inhaler in FIGS. 11-13, the inhaler 400 includes a holding chamber 402 and a mouthpiece 408, which can be separate from (FIG. 11) or integral with (FIGS. 12-13) the holding chamber. The inhaler further includes a medicament holding cassette 414, which has a plurality of holding portions 416 that hold a plurality of dose of medication, each of which can be subsequently exposed to the interior of the holding chamber. One or more air entry passageways 418 are directed at the holding' portions 416 and fluidize the medication within the holding chamber, wherein it can be subsequently inhaled through the mouthpiece. Various aspects of the inhaler are further disclosed and shown in U.S. Patent No. 6,116,239, the entire disclosure of which may be referred to herein.
It should be understood that any or all of the various components of the inhalers 400, including the holding chambers 402, mouthpieces 408, air intake passageways 418, cassettes 414, and/or holding portions 416, can be made of one or more of the various antistatic materials described herein.
Various nasal inhalers 500, an example of which is shown in FIG. 16, may also include one or more of a holding chamber 502 having an input and 510 and an output end formed as an outlet 506, an actuator (not shown) and an adapter 504, one or more of which may be made of the various antistatic materials described herein. One or more inlet valves 508 may be provided in the holding chamber 502. Various exemplary nasal inhalers and applicators are disclosed for example in U.S. Patent No. 6,644,305 dated November 11, 2003, and U.S. Patent No. 6,745,760 dated June 8, 2004, the entire disclosures of which may be referred to herein.
Although the present invention has been described with reference to preferred embodiments, those skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention. As such, it is intended that the foregoing detailed description be regarded as illustrative rather than limiting and that it is the appended claims, including all equivalents thereof, which are intended to define the scope of the invention.
Although the present invention has been described with reference to preferred embodiments, those skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention. As such, it is intended that the foregoing detailed description be regarded as illustrative rather than limiting and that it is the appended claims, including all equivalents thereof, which are intended to define the scope of the invention.
Claims (17)
1. A medication delivery apparatus comprising:
an antistatic holding chamber comprising a plastic material having a surface resistivity of between about 10E10 and about 10E12 ohm/sq, wherein said holding chamber has an input end and an output end spaced apart along a longitudinal axis;
a patient interface component connected to said output end and comprising an interior surface defining a flow passage; and a one-way valve disposed adjacent said output end, said one-way valve moveable between an open position and a closed position, wherein said one-way valve has a central opening when in said open position, said central opening defining a flow path along said longitudinal axis, wherein no portion of said interior surface of said patient interface component downstream of said one-way valve intersects said flow path in an orthogonal relationship.
an antistatic holding chamber comprising a plastic material having a surface resistivity of between about 10E10 and about 10E12 ohm/sq, wherein said holding chamber has an input end and an output end spaced apart along a longitudinal axis;
a patient interface component connected to said output end and comprising an interior surface defining a flow passage; and a one-way valve disposed adjacent said output end, said one-way valve moveable between an open position and a closed position, wherein said one-way valve has a central opening when in said open position, said central opening defining a flow path along said longitudinal axis, wherein no portion of said interior surface of said patient interface component downstream of said one-way valve intersects said flow path in an orthogonal relationship.
2. The apparatus of claim 1 wherein said plastic material comprises a polypropylene material.
3. The apparatus of claim 1 further comprising a backpiece separate from said holding chamber and comprising an elastomeric material having a surface resistivity of between about 10E10 and about 10E12 ohm/sq, wherein said backpiece is connected to said input end of said holding chamber.
4. The apparatus of claim 3 wherein said backpiece comprises an opening formed therethrough, said opening shaped and adapted to receive a portion of a pressurized metered dose inhaler.
5. The apparatus of claim 1 wherein said material is selected from the group consisting of polypropylene, polycarbonate, polystyrene, nylon, acrylonitrile butadiene styrene, high density polyethylene, acetal, polybutylene terephthalate, and polyethylene terephthalate glycol.
6. The apparatus of claim 1 wherein at least a portion of said holding chamber is see-through.
7 The apparatus of claim 1 wherein said surface resistivity of said plastic material is between about l0 E 10 and about l0E11 ohm/sq.
8. The apparatus of claim 1 further comprising a second antistatic component separate from said holding chamber and comprising a material having a surface resistivity of between about lOE10 and about lOE12 ohm/sq, and wherein said second antistatic component is connected to said holding chamber.
9. The apparatus of claim 8 wherein said second antistatic component comprises said patient interface component connected to said output end of said holding chamber.
10. The apparatus of claim 8 wherein said second antistatic component comprises a backpiece connected to said input end of said holding chamber.
11. The apparatus of claim 10 wherein said backpiece comprises an elastomeric material.
12. The apparatus of claim 10 wherein said backpiece comprises an opening formed therethrough, said opening shaped and adapted to receive a portion of a pressurized metered dose inhaler.
13. The apparatus of claim 10 wherein said material comprises a thermoplastic elastomer material.
14. The apparatus of claim 8 wherein said material of said second antistatic component is selected from the group consisting of a polyurethane elastomer, polyester elastomer, styrenic elastomer and olefinic elastomer.
15. The apparatus of claim 8 wherein at least a portion of said holding chamber and said second antistatic component is see-through.
16. The apparatus of claim 1 wherein said patient interface component comprises a mouthpiece.
17. The apparatus of claim 16 wherein said interior surface of said mouthpiece is made of a material having a surface resistivity of greater than lOE12 ohm/sq.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2736640A CA2736640C (en) | 2003-04-16 | 2004-04-14 | Antistatic medication delivery apparatus |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46328803P | 2003-04-16 | 2003-04-16 | |
US60/463,288 | 2003-04-16 | ||
PCT/IB2004/001132 WO2004091704A1 (en) | 2003-04-16 | 2004-04-14 | Antistatic medication delivery apparatus |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2736640A Division CA2736640C (en) | 2003-04-16 | 2004-04-14 | Antistatic medication delivery apparatus |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2520708A1 CA2520708A1 (en) | 2004-10-28 |
CA2520708C true CA2520708C (en) | 2011-06-21 |
Family
ID=33300058
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2520708A Expired - Lifetime CA2520708C (en) | 2003-04-16 | 2004-04-14 | Antistatic medication delivery apparatus |
CA2785936A Abandoned CA2785936A1 (en) | 2003-04-16 | 2004-04-14 | Antistatic medication delivery apparatus |
CA2736640A Expired - Lifetime CA2736640C (en) | 2003-04-16 | 2004-04-14 | Antistatic medication delivery apparatus |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2785936A Abandoned CA2785936A1 (en) | 2003-04-16 | 2004-04-14 | Antistatic medication delivery apparatus |
CA2736640A Expired - Lifetime CA2736640C (en) | 2003-04-16 | 2004-04-14 | Antistatic medication delivery apparatus |
Country Status (6)
Country | Link |
---|---|
US (2) | US7360537B2 (en) |
EP (2) | EP1613380A1 (en) |
JP (1) | JP2006523486A (en) |
CA (3) | CA2520708C (en) |
MX (1) | MXPA05011177A (en) |
WO (1) | WO2004091704A1 (en) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5823179A (en) | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
AU2002238801A1 (en) * | 2001-03-20 | 2002-10-03 | Trudell Medical International | Nebulizer apparatus and method |
US20030205226A1 (en) | 2002-05-02 | 2003-11-06 | Pre Holding, Inc. | Aerosol medication inhalation system |
US6904908B2 (en) | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
US7849853B2 (en) * | 2003-02-11 | 2010-12-14 | Trudell Medical International | Ventilator circuit and the method for the use thereof |
US7360537B2 (en) * | 2003-04-16 | 2008-04-22 | Trudell Medical International | Antistatic medication delivery apparatus |
DE102005010965B3 (en) * | 2005-03-10 | 2006-08-03 | Medspray Xmems Bv | Medical inhaler for personal use, comprises a mixing channel with an outlet with a medicament injection area that is designed to be flush with the surface of the channel to less than a millimeter (mm) and ideally less than a tenth of a mm |
US8028697B2 (en) | 2005-04-28 | 2011-10-04 | Trudell Medical International | Ventilator circuit and method for the use thereof |
WO2007041669A2 (en) * | 2005-10-04 | 2007-04-12 | Sp Medical Llc | Metered dose inhaler having spacing device |
DE102006009637A1 (en) * | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhaler with mouthpiece with microbiological protection |
MX2009001944A (en) | 2006-08-21 | 2009-04-16 | Trudell Medical Int | Respiratory muscle endurance training device and method for the use thereof. |
US8141551B2 (en) * | 2007-02-16 | 2012-03-27 | Destal Industries, Inc. | Mouthpiece and flow rate controller for intrapulmonary delivery devices |
US20080210225A1 (en) * | 2007-03-01 | 2008-09-04 | Rapha Institute For Health | Disposable antistatic spacer |
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US8151794B2 (en) | 2007-04-24 | 2012-04-10 | Trudell Medical International | Aerosol delivery system |
GB2451225B (en) * | 2007-05-15 | 2009-07-08 | Bespak Plc | Improvements in or relating to dispensing apparatus |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
WO2009105515A2 (en) | 2008-02-21 | 2009-08-27 | Trudell Medical International | Respiratory muscle endurance training device and method for the use thereof |
US8251876B2 (en) | 2008-04-22 | 2012-08-28 | Hill-Rom Services, Inc. | Breathing exercise apparatus |
EP2135632A1 (en) * | 2008-06-20 | 2009-12-23 | Boehringer Ingelheim International Gmbh | Inhalator |
US20100000523A1 (en) * | 2008-07-07 | 2010-01-07 | Rosh Melvin S | Unichamber |
EP2179760B1 (en) | 2008-10-22 | 2013-02-27 | Trudell Medical International | Modular Aerosol Delivery System |
EP2414560B1 (en) | 2009-03-31 | 2013-10-23 | Boehringer Ingelheim International GmbH | Method for coating a surface of a component |
JP5763053B2 (en) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adapter, inhaler and atomizer |
CN102458541A (en) | 2009-06-25 | 2012-05-16 | 贝林格尔.英格海姆维特梅迪卡有限公司 | Inhaler |
EP2504051B1 (en) | 2009-11-25 | 2019-09-04 | Boehringer Ingelheim International GmbH | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
EA026241B1 (en) | 2009-11-25 | 2017-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Nebulizer |
US10016567B2 (en) * | 2009-12-16 | 2018-07-10 | Koninklijke Philips N.V. | Color identification for drug delivery system |
EP2558149A1 (en) * | 2010-04-13 | 2013-02-20 | Mahmut Bilgic | Dry powder inhaler mouthpiece button |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
EP2618876B1 (en) * | 2010-09-21 | 2018-11-14 | Koninklijke Philips N.V. | Valved holding chamber including valve retention system |
CN102553039B (en) * | 2010-12-17 | 2014-10-29 | 陈庆堂 | Medicinal powder suction nozzle and application |
WO2012130757A1 (en) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medical device comprising a container |
RO127873A2 (en) * | 2011-04-04 | 2012-10-30 | Salt Pharma S.R.L. | Bifunctional inhalation device |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
ES2687150T3 (en) | 2011-06-06 | 2018-10-23 | Trudell Medical International | Oscillating positive expiratory pressure device |
US8695589B2 (en) | 2011-12-06 | 2014-04-15 | Anthony J. Mullane | Inhaler assist device |
US9180271B2 (en) | 2012-03-05 | 2015-11-10 | Hill-Rom Services Pte. Ltd. | Respiratory therapy device having standard and oscillatory PEP with nebulizer |
WO2013152894A1 (en) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Atomiser with coding means |
US9364622B2 (en) * | 2012-04-20 | 2016-06-14 | Fsc Laboratories, Inc. | Inhalation devices and systems and methods including the same |
AU2013307389A1 (en) | 2012-08-29 | 2015-03-19 | Chiesi Farmaceutici S.P.A. | Aerosol inhalation device |
US9517315B2 (en) | 2012-11-30 | 2016-12-13 | Trudell Medical International | Oscillating positive expiratory pressure device |
CA151549S (en) | 2013-02-14 | 2014-06-04 | Clement Clarke Int Ltd | Spacer for an asthma inhaler |
USD735316S1 (en) | 2013-03-11 | 2015-07-28 | Fsc Laboratories, Inc. | Inhalation spacer |
EP3345643B1 (en) | 2013-03-15 | 2021-01-06 | Chris V. Ciancone | Inhaler spacer and storage apparatus |
WO2014140774A1 (en) | 2013-03-15 | 2014-09-18 | Trudell Medical International | Delivery device and kit, and method of use |
US9700688B2 (en) | 2013-03-15 | 2017-07-11 | Trudell Medical International | Delivery device and kit, and method of use |
EP3030298B1 (en) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Nebulizer |
ES2836977T3 (en) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizer |
WO2015024653A1 (en) | 2013-08-20 | 2015-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
EP4295880A2 (en) | 2013-08-20 | 2023-12-27 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
NZ714524A (en) | 2013-08-20 | 2020-07-31 | Boehringer Ingelheim Vetmedica Gmbh | Inhaler |
DE202014006618U1 (en) | 2013-08-20 | 2014-11-24 | Boehringer Ingelheim Vetmedica Gmbh | inhaler |
KR102502328B1 (en) * | 2013-08-20 | 2023-02-23 | 베링거잉겔하임베트메디카게엠베하 | Inhaler |
HU4880U (en) | 2013-08-20 | 2018-05-02 | Boehringer Ingelheim Vetmedica Gmbh | Inhalator |
WO2015066562A2 (en) * | 2013-10-31 | 2015-05-07 | Knox Medical Diagnostics | Systems and methods for monitoring respiratory function |
PL3139979T3 (en) | 2014-05-07 | 2023-12-27 | Boehringer Ingelheim International Gmbh | Unit, nebulizer and method |
WO2015169430A1 (en) | 2014-05-07 | 2015-11-12 | Boehringer Ingelheim International Gmbh | Nebulizer |
MX2016014403A (en) | 2014-05-07 | 2017-01-20 | Boehringer Ingelheim Int | Container, indicator device, and nebulizer. |
US11116918B2 (en) * | 2015-03-02 | 2021-09-14 | Abithas, Inc. | Delivery system for metered dose inhalers |
KR102217768B1 (en) * | 2015-03-11 | 2021-02-19 | 알렉스자 파마스티칼즈, 인크. | Use of antistatic materials in airways for thermal aerosol condensation processes |
WO2017017657A1 (en) | 2015-07-30 | 2017-02-02 | Trudell Medical International | Combined respiratory muscle training and oscillating positive expiratory pressure device |
US10894142B2 (en) * | 2016-03-24 | 2021-01-19 | Trudell Medical International | Respiratory care system with electronic indicator |
AU2017253951B2 (en) * | 2016-04-18 | 2021-08-12 | Inspiring Pty Ltd | Spacer device for an inhaler |
MX2018014121A (en) | 2016-05-19 | 2019-04-29 | Trudell Medical Int | Smart valved holding chamber. |
US10786638B2 (en) | 2016-07-08 | 2020-09-29 | Trudell Medical International | Nebulizer apparatus and method |
EP3984579A1 (en) | 2016-07-08 | 2022-04-20 | Trudell Medical International | Smart oscillating positive expiratory pressure device |
FR3054135A1 (en) * | 2016-07-22 | 2018-01-26 | La Diffusion Technique Francaise | INHALATION DEVICE, TREATMENT SYSTEM, AND METHOD FOR IMPLEMENTING THE SAME |
WO2018104805A1 (en) | 2016-12-09 | 2018-06-14 | Trudell Medical International | Smart nebulizer |
CN110730674B (en) * | 2017-04-18 | 2022-02-01 | 励志私人有限公司 | Dry powder inhaler and spacer for a dry powder inhaler |
JP7312754B2 (en) | 2018-01-04 | 2023-07-21 | トゥルーデル メディカル インターナショナル | Smart vibrating positive expiratory pressure device |
JP7313439B2 (en) | 2018-06-04 | 2023-07-24 | トゥルーデル メディカル インターナショナル | Positive air pressure therapy device, kit thereof, and method of use and assembly |
JP7427660B2 (en) | 2018-06-04 | 2024-02-05 | トゥルーデル メディカル インターナショナル | Holding chamber with smart valve |
WO2019236662A1 (en) | 2018-06-05 | 2019-12-12 | Teleflex Medical Incorporated | Valved spacer for inhalation device |
US11617853B2 (en) | 2018-11-30 | 2023-04-04 | Trudell Medical International | Nasal mask with aromatic dispenser |
US11266797B2 (en) | 2019-03-28 | 2022-03-08 | Thayer Medical Corporation | Collapsible, disposable medication inhalation spacer and method |
US11638792B2 (en) | 2019-03-28 | 2023-05-02 | Thayer Medical Corporation | Collapsible, disposable medication inhalation spacer and method |
US11383051B2 (en) | 2019-03-28 | 2022-07-12 | Thayer Medical Corporation | Collapsible, disposable medication inhalation spacer and method |
US10589040B1 (en) | 2019-03-28 | 2020-03-17 | Thayer Medical Corporation | Collapsible, disposable MDI spacer and method |
EP3946529A4 (en) | 2019-03-28 | 2023-01-04 | Thayer Medical Corporation | Collapsible, disposable medication inhalation spacer and method |
WO2020219921A1 (en) * | 2019-04-25 | 2020-10-29 | Sensory Cloud, Llc | Systems, methods, and articles for delivery of substances in vessels |
CN114269410A (en) * | 2019-05-24 | 2022-04-01 | 蓝海集团有限责任公司 | Compact spacer for metered dose inhalers |
WO2021038467A1 (en) | 2019-08-27 | 2021-03-04 | Trudell Medical International | Smart oscillating positive expiratory pressure device |
USD1010101S1 (en) | 2020-09-18 | 2024-01-02 | Trudell Medical International | Holding chamber |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE6600376U (en) * | 1964-06-15 | 1969-01-23 | Asmund S Laerdal | ELASTIC BAG FOR AIR OR OXYGEN SUPPLY IN RESEARCH DEVICES |
GB1188003A (en) * | 1967-07-04 | 1970-04-15 | Sterwin Ag | Improvements in or relating to Aerosol Dispensers. |
US3896101A (en) * | 1971-04-30 | 1975-07-22 | Askew Anthony B | Additive for plastic materials |
US4183361A (en) * | 1978-02-27 | 1980-01-15 | Russo Ronald D | Respiratory exercising device |
US4253468A (en) * | 1978-08-14 | 1981-03-03 | Steven Lehmbeck | Nebulizer attachment |
GB2080688B (en) * | 1980-07-29 | 1984-10-31 | Dent Hugh Robert | Sterilising fitments for injection devices |
DE3043377A1 (en) * | 1980-11-17 | 1982-07-01 | Brugger, Inge, 8130 Starnberg | SPRAYER |
US4509515A (en) * | 1982-02-23 | 1985-04-09 | Fisons Plc | Inhalation device |
US4809692A (en) * | 1986-01-31 | 1989-03-07 | Trudell Medical | Pediatric asthmatic medication inhaler |
US4834083A (en) * | 1988-05-12 | 1989-05-30 | Minnesota Mining And Manufacturing Company | Aerosol device |
US4832015A (en) * | 1988-05-19 | 1989-05-23 | Trudell Medical | Pediatric asthmatic inhaler |
US4984158A (en) * | 1988-10-14 | 1991-01-08 | Hillsman Dean | Metered dose inhaler biofeedback training and evaluation system |
US5012804A (en) | 1989-03-06 | 1991-05-07 | Trudell Medical | Medication inhaler with adult mask |
US5012803A (en) | 1989-03-06 | 1991-05-07 | Trudell Medical | Modular medication inhaler |
GB8909891D0 (en) * | 1989-04-28 | 1989-06-14 | Riker Laboratories Inc | Device |
ES2089228T3 (en) * | 1990-09-12 | 1996-10-01 | Hans Bisgaard | INHALER DEVICE. |
GB9021433D0 (en) * | 1990-10-02 | 1990-11-14 | Atomic Energy Authority Uk | Power inhaler |
AU651882B2 (en) * | 1991-05-14 | 1994-08-04 | Visiomed Group Limited | Aerosol inhalation device |
CA2112674C (en) * | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
US5431154A (en) * | 1991-11-29 | 1995-07-11 | Seigel; David | Incentive metered dose inhaler |
EP0546964B1 (en) * | 1991-12-10 | 1997-04-09 | TDK Corporation | An ultrasonic wave nebulizer |
WO1993011817A1 (en) * | 1991-12-16 | 1993-06-24 | The University Of Melbourne | Improvements in the administration of aerosol compounds |
FI95873C (en) * | 1992-10-15 | 1996-04-10 | Orion Yhtymae Oy | Valve for use with an inhaler |
NZ250105A (en) * | 1992-11-09 | 1996-07-26 | Monaghan Canadian Ltd | Inhalator mask; one-way valve opens upon exhalation |
AU119600S (en) * | 1993-01-21 | 1994-03-07 | Boehringer Ingelheim Kg | Inhaler device |
US5899201A (en) * | 1993-05-26 | 1999-05-04 | Minnesota Mining And Manufacturing Company | Aerosol actuator |
US5383470A (en) * | 1993-09-20 | 1995-01-24 | Steve Novak | Portable spirometer |
EP0663241B1 (en) * | 1993-12-17 | 1998-07-15 | PARI GmbH Spezialisten für effektive Inhalation | Spray nozzle |
SE9400257D0 (en) | 1994-01-27 | 1994-01-27 | Astra Ab | spacer |
SE9401220D0 (en) * | 1994-04-11 | 1994-04-11 | Astra Ab | Valve |
US5848588A (en) * | 1994-05-25 | 1998-12-15 | Trudell Medical Group | Backpiece for receiving an MDI adapter in an aerosolization spacer |
CA2124410A1 (en) * | 1994-05-26 | 1995-11-27 | Jean-Paul Praud | Device for the simultaneous delivery of beta 2 agonists and oxygen to a patient |
US20020005196A1 (en) * | 1994-11-15 | 2002-01-17 | Pari Gmbh Spezialisten Fur Effektive Inhalation | Portable inhalator compressor device |
US5613489A (en) * | 1994-12-07 | 1997-03-25 | Westmed, Inc. | Patient respiratory system drug applicator |
US5522380A (en) * | 1995-01-18 | 1996-06-04 | Dwork; Paul | Metered dose medication adaptor with improved incentive spirometer |
WO1996024407A1 (en) * | 1995-02-10 | 1996-08-15 | Hougen Everett D | A portable, personal breathing apparatus |
DE19519763C2 (en) * | 1995-05-30 | 1999-08-05 | Pari Gmbh | Inhalation device compressor with improved membrane set |
DE19520622C2 (en) * | 1995-06-06 | 2003-05-15 | Pari Gmbh | Device for atomizing fluids |
US5758638A (en) * | 1995-07-24 | 1998-06-02 | Kreamer; Jeffry W. | Indicator for a medicament inhaler |
US5738087A (en) * | 1995-09-21 | 1998-04-14 | King; Russell W. | Aerosol medication delivery system |
US6026809A (en) * | 1996-01-25 | 2000-02-22 | Microdose Technologies, Inc. | Inhalation device |
US5823179A (en) * | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
DE19616573C2 (en) * | 1996-04-25 | 1999-03-04 | Pari Gmbh | Use of subcritical blowing agent mixtures and aerosols for the micronization of drugs with the help of dense gases |
US5704344A (en) * | 1996-09-06 | 1998-01-06 | Cole; Jeanne M. | Device for relieving anxiety in respiratory patients |
SE9603804D0 (en) * | 1996-10-16 | 1996-10-16 | Aga Ab | Method and apparatus for producing a atomized aerosol |
JP2002515794A (en) | 1996-11-01 | 2002-05-28 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Storage resistant spacers for metered dose inhalers |
US5765553A (en) * | 1996-11-27 | 1998-06-16 | Diemolding Corporation | Aerosol medication delivery facemask adapter |
US5896857A (en) * | 1996-12-20 | 1999-04-27 | Resmed Limited | Valve for use in a gas delivery system |
US6044859A (en) * | 1997-03-03 | 2000-04-04 | Filtertek Inc | Valve apparatus and method |
US5865172A (en) * | 1997-04-08 | 1999-02-02 | The Board Of Regents Of The University Of Texas System | Method and apparatus for induction of inhaled pharmacological agent by a pediatric patient |
DE19734022C2 (en) * | 1997-08-06 | 2000-06-21 | Pari Gmbh | Inhalation therapy device with a valve to limit the flow of inspiration |
CA2212430A1 (en) | 1997-08-07 | 1999-02-07 | George Volgyesi | Inhalation device |
US6044841A (en) * | 1997-08-29 | 2000-04-04 | 1263152 Ontario Inc. | Breath actuated nebulizer with valve assembly having a relief piston |
US6293279B1 (en) * | 1997-09-26 | 2001-09-25 | Trudell Medical International | Aerosol medication delivery apparatus and system |
US6345617B1 (en) * | 1997-09-26 | 2002-02-12 | 1263152 Ontario Inc. | Aerosol medication delivery apparatus and system |
US5855202A (en) * | 1997-10-08 | 1999-01-05 | Andrade; Joseph R. | Aerosol holding chamber for a metered-dose inhaler |
NZ504021A (en) * | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
US5925831A (en) * | 1997-10-18 | 1999-07-20 | Cardiopulmonary Technologies, Inc. | Respiratory air flow sensor |
GB9827370D0 (en) * | 1998-01-16 | 1999-02-03 | Pari Gmbh | Mouthpiece for inhalation therapy units |
US6039042A (en) * | 1998-02-23 | 2000-03-21 | Thayer Medical Corporation | Portable chamber for metered dose inhaler dispensers |
US6679252B2 (en) * | 1998-02-23 | 2004-01-20 | Thayer Medical Corporation | Collapsible, disposable MDI spacer and method |
US6026807A (en) * | 1998-02-27 | 2000-02-22 | Diemolding Corporation | Metered dose inhaler cloud chamber |
DE19817417A1 (en) * | 1998-04-18 | 1999-10-21 | Pfeiffer Erich Gmbh & Co Kg | Dispenser for media, especially powder |
US6578571B1 (en) * | 1998-04-20 | 2003-06-17 | Infamed Ltd. | Drug delivery device and methods therefor |
DE19827228C2 (en) * | 1998-06-18 | 2000-07-13 | Pari Gmbh | Liquid atomizer device |
DE19846382C1 (en) * | 1998-10-08 | 2000-07-06 | Pari Gmbh | Counter and its use in inhalers, nebulizers or similar metered dose inhalers |
US6257231B1 (en) * | 1998-12-03 | 2001-07-10 | Ferraris Medical, Inc. | Aerosol enhancement |
ZA9811257B (en) * | 1998-12-09 | 2001-01-31 | App Sub Cipla Ltd 8 8 2000 | Inhalation device. |
US6253767B1 (en) * | 1998-12-10 | 2001-07-03 | Robert F. Mantz | Gas concentrator |
US6584971B1 (en) * | 1999-01-04 | 2003-07-01 | Medic-Aid Limited | Drug delivery apparatus |
GB9911388D0 (en) * | 1999-05-18 | 1999-07-14 | Glaxo Group Ltd | Dispenser |
US6367471B1 (en) * | 1999-11-01 | 2002-04-09 | Sheffield Pharmaceuticals, Inc. | Internal vortex mechanism for inhaler device |
US6962151B1 (en) * | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
US6240917B1 (en) * | 1999-12-20 | 2001-06-05 | Joseph R. Andrade | Aerosol holding chamber for a metered-dose inhaler |
DE19962110C2 (en) * | 1999-12-22 | 2003-06-12 | Pari Gmbh | Inhalation nebulizer with one-piece valve element |
US6412481B1 (en) * | 1999-12-23 | 2002-07-02 | Robert Bienvenu | Sealed backpressure attachment device for nebulizer |
AU4867001A (en) * | 2000-04-11 | 2001-10-23 | Trudell Medical International | Aerosol delivery apparatus with positive expiratory pressure capacity |
US20040089292A1 (en) | 2000-07-06 | 2004-05-13 | Pollet Hilde Rachel Maria | Dispensing apparatus |
DE10036906B4 (en) * | 2000-07-28 | 2008-06-19 | Pari GmbH Spezialisten für effektive Inhalation | Liquid atomiser |
US6595203B1 (en) * | 2000-11-28 | 2003-07-22 | Forrest M. Bird | Apparatus for administering intermittent percussive ventilation and unitary breathing head assembly for use therein |
DE10102846B4 (en) * | 2001-01-23 | 2012-04-12 | Pari Pharma Gmbh | aerosol generator |
US7013896B2 (en) * | 2001-05-08 | 2006-03-21 | Trudell Medical International | Mask with inhalation valve |
DE10126808C1 (en) * | 2001-06-01 | 2002-08-14 | Pari Gmbh | inhalation mask |
DE10126807C2 (en) * | 2001-06-01 | 2003-12-04 | Pari Gmbh | Inhalation therapy device with a valve to limit the flow of inspiration |
DE50102690D1 (en) * | 2001-10-18 | 2004-07-29 | Pari Gmbh | Inhalation therapy device |
DE50106644D1 (en) * | 2001-10-18 | 2005-08-04 | Pari Gmbh | Inhalation therapy device |
US6708688B1 (en) * | 2001-12-11 | 2004-03-23 | Darren Rubin | Metered dosage inhaler system with variable positive pressure settings |
US6679250B2 (en) * | 2002-03-06 | 2004-01-20 | Joseph J. Walker | Combination inhalation therapeutic and exhalation measuring device |
US20030205226A1 (en) * | 2002-05-02 | 2003-11-06 | Pre Holding, Inc. | Aerosol medication inhalation system |
US6904908B2 (en) * | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
DE10226334B4 (en) * | 2002-06-13 | 2005-09-01 | Pari GmbH Spezialisten für effektive Inhalation | Device for detecting parameters of an aerosol, in particular in inhalation therapy devices |
US6955169B2 (en) * | 2002-06-27 | 2005-10-18 | Khan Khaja H | Inhaler device |
DE10229889A1 (en) * | 2002-07-03 | 2004-01-29 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation therapy device |
DE10250625A1 (en) * | 2002-10-30 | 2004-05-19 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation therapy device |
EP1417958A1 (en) * | 2002-11-08 | 2004-05-12 | Pari GmbH | Wet granulation process |
US7051731B1 (en) * | 2002-11-15 | 2006-05-30 | Rogerson L Keith | Oxygen delivery system |
US7022764B2 (en) * | 2002-12-18 | 2006-04-04 | General Electric Company | Static dissipating resin composition and methods for manufacture thereof |
US7360537B2 (en) * | 2003-04-16 | 2008-04-22 | Trudell Medical International | Antistatic medication delivery apparatus |
DE10322505B4 (en) * | 2003-05-19 | 2009-11-05 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation therapy mask and device for animals |
US20060065267A1 (en) * | 2004-03-18 | 2006-03-30 | Pari Innovative Manufacturers, Inc. | Breath enhanced nebulizer with interchangeable top portions |
DE102004041667A1 (en) * | 2004-08-27 | 2006-03-02 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation therapy device |
US8028697B2 (en) * | 2005-04-28 | 2011-10-04 | Trudell Medical International | Ventilator circuit and method for the use thereof |
-
2004
- 2004-04-08 US US10/821,260 patent/US7360537B2/en active Active
- 2004-04-14 MX MXPA05011177A patent/MXPA05011177A/en active IP Right Grant
- 2004-04-14 CA CA2520708A patent/CA2520708C/en not_active Expired - Lifetime
- 2004-04-14 CA CA2785936A patent/CA2785936A1/en not_active Abandoned
- 2004-04-14 CA CA2736640A patent/CA2736640C/en not_active Expired - Lifetime
- 2004-04-14 EP EP04727338A patent/EP1613380A1/en not_active Ceased
- 2004-04-14 WO PCT/IB2004/001132 patent/WO2004091704A1/en active Application Filing
- 2004-04-14 EP EP10012600A patent/EP2314337A1/en not_active Withdrawn
- 2004-04-14 JP JP2006506468A patent/JP2006523486A/en not_active Withdrawn
-
2008
- 2008-03-11 US US12/075,470 patent/US20080257345A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2520708A1 (en) | 2004-10-28 |
US20050005929A1 (en) | 2005-01-13 |
EP1613380A1 (en) | 2006-01-11 |
EP2314337A1 (en) | 2011-04-27 |
CA2736640C (en) | 2012-10-09 |
WO2004091704A1 (en) | 2004-10-28 |
CA2785936A1 (en) | 2004-10-28 |
US7360537B2 (en) | 2008-04-22 |
JP2006523486A (en) | 2006-10-19 |
US20080257345A1 (en) | 2008-10-23 |
CA2736640A1 (en) | 2004-10-28 |
MXPA05011177A (en) | 2006-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2520708C (en) | Antistatic medication delivery apparatus | |
US10881816B2 (en) | Medication delivery apparatus and system and methods for the use and assembly thereof | |
EP2379143B1 (en) | Valved holding chamber and mask therefor | |
US8028697B2 (en) | Ventilator circuit and method for the use thereof | |
US9364621B2 (en) | Valved holding chamber including valve retention system | |
US9700688B2 (en) | Delivery device and kit, and method of use | |
US20080066743A1 (en) | Aerosol medication delivery apparatus with narrow orifice | |
WO2010076683A1 (en) | System and method for dispensing medicament into a ventilator circuit | |
US20150314086A1 (en) | Powder inhaler, system and methods | |
US20160030687A1 (en) | Delivery device and kit, and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |